These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30324343)

  • 61. Reply to the letter to the editor 'second-line chemotherapy in advanced biliary cancer: the present now will later be past' by Vivaldi et al.
    Lamarca A; Hubner RA; Ryder WD; Valle JW
    Ann Oncol; 2014 Dec; 25(12):2444-2445. PubMed ID: 25139549
    [No Abstract]   [Full Text] [Related]  

  • 62. Outcome of second-line chemotherapy for biliary tract cancer.
    Bridgewater J; Palmer D; Cunningham D; Iveson T; Gillmore R; Waters J; Harrison M; Wasan H; Corrie P; Valle J
    Eur J Cancer; 2013 Apr; 49(6):1511. PubMed ID: 23265701
    [No Abstract]   [Full Text] [Related]  

  • 63. Optimizing renal function and outcome of patients with cT2 renal cell carcinoma.
    Santoni M; Maiorani G; Faloppi L; Di Nunno V; Gatto L; Massari F; Battelli N
    Ann Transl Med; 2019 Mar; 7(Suppl 1):S39. PubMed ID: 31032318
    [No Abstract]   [Full Text] [Related]  

  • 64. A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group.
    Kobayashi S; Nagano H; Tomokuni A; Gotoh K; Sakai D; Hatano E; Seo S; Terajima H; Uchida Y; Ajiki T; Satake H; Kamei K; Tohyama T; Hirose T; Ikai I; Morita S; Ioka T;
    Ann Surg; 2019 Aug; 270(2):230-237. PubMed ID: 30339627
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study.
    Rizzo A; Salati M; Frega G; Merz V; Caputo F; Di Federico A; Palloni A; Carloni R; Ricci AD; Gadaleta-Caldarola G; Messina C; Spallanzani A; Gelsomino F; Benatti S; Luppi G; Melisi D; Dominici M; Brandi G
    Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363500
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma.
    Massa A; Peraldo-Neia C; Vita F; Varamo C; Basiricò M; Raggi C; Bernabei P; Erriquez J; Sarotto I; Leone F; Marchiò S; Cavalloni G; Aglietta M
    Front Oncol; 2022; 12():771418. PubMed ID: 35251961
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Chemotherapy for Biliary Tract Cancer in 2021.
    Sasaki T; Takeda T; Okamoto T; Ozaka M; Sasahira N
    J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300274
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient.
    Peraldo-Neia C; Massa A; Vita F; Basiricò M; Raggi C; Bernabei P; Ostano P; Casorzo L; Panero M; Leone F; Cavalloni G; Aglietta M
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922695
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A review of systemic therapy in biliary tract carcinoma.
    Jansen H; Pape UF; Utku N
    J Gastrointest Oncol; 2020 Aug; 11(4):770-789. PubMed ID: 32953160
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience.
    Wu CE; Chou WC; Hsieh CH; Chang JW; Lin CY; Yeh CN; Chen JS
    BMC Cancer; 2020 May; 20(1):422. PubMed ID: 32410631
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases.
    Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Oyama H; Kanai S; Suzuki T; Sato T; Hakuta R; Ishigaki K; Takeda T; Saito T; Mizuno S; Kogure H; Tada M; Koike K
    Invest New Drugs; 2018 Dec; 36(6):1093-1102. PubMed ID: 30324343
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study.
    Walter T; Horgan AM; McNamara M; McKeever L; Min T; Hedley D; Serra S; Krzyzanowska MK; Chen E; Mackay H; Feld R; Moore M; Knox JJ
    Eur J Cancer; 2013 Jan; 49(2):329-35. PubMed ID: 22947649
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prognostic Factors for the Selection of Patients Eligible for Second-Line Chemotherapy in Advanced Biliary Tract Cancer.
    Kang EJ; Choi YJ; Kim JS; Park KH; Oh SC; Seo JH; Kim HJ; Kang KW; Yu ES; Shin SW; Kim YH; Kim JS
    Chemotherapy; 2014; 60(2):91-98. PubMed ID: 25720697
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Systemic treatment in advanced biliary cancers: A multicenter Australian analysis and review.
    Brungs D; Aghmesheh M; Sjoquist K; Goldstein D
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e291-e297. PubMed ID: 27860270
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.
    Sebbagh S; Roux J; Dreyer C; Neuzillet C; de Gramont A; Orbegoso C; Hentic O; Hammel P; de Gramont A; Raymond E; André T; Chibaudel B; Faivre S
    Acta Oncol; 2016; 55(9-10):1168-1174. PubMed ID: 27333436
    [TBL] [Abstract][Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.